PROCEPT BioRobotics investors urged to seek lead plaintiff status in securities suit
A law firm says investors who lost money in PROCEPT BioRobotics Corp. shares may contact it by Sept. 22, 2026, over an ongoing securities fraud class action.
A law firm says investors who lost money in PROCEPT BioRobotics Corp. shares may contact it by Sept. 22, 2026, to seek lead plaintiff status in an ongoing securities fraud class action.
The PR Newswire release, issued Aug. 31, 2026, by the Law Offices of Howard G. Smith, says the proposed class period runs from Feb. 28, 2024, through Feb. 25, 2026. It names PROCEPT BioRobotics Corporation and references the ticker PRCT.
According to the notice, the complaint alleges the company made misleading statements about its business, operations and financial condition. The allegations have not been tested in court.
The notice says the complaint alleges the company used an extensive discount program to encourage bulk handpiece orders beyond procedure demand. The release says that practice allegedly pulled sales forward from future periods and inflated reported U.S. handpiece unit sales and revenue.
The release also says the complaint alleges customer orders exceeded underlying procedure demand throughout the class period and that the gap widened over time. By the end of the period, the notice says, the alleged surplus created more than 10,000 excess units of field inventory and overstocking.
The release says the company overstated handpiece unit sales and field system utilization and faced undisclosed operational and financial risks. It does not include a response from PROCEPT BioRobotics.
The notice says investors with losses may contact the law firm before the Sept. 22 deadline if they want to ask the court to appoint them lead plaintiff. It also says class members do not need to take immediate action, may choose their own counsel or may remain absent class members.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.